New Insights into Retinopathy: Research from Australia, Japan, and the United States

Strategic Insights -

Research from scientists in Australia, Japan, and the United States has shed new light on retinopathy, a leading cause of vision loss worldwide. Recent studies have focused on understanding the underlying mechanisms of angiogenesis, the formation of new blood vessels, which is a hallmark of retinopathy. Three studies have made significant contributions to this area, providing valuable insights into potential treatments for this devastating disease.

Key Takeaways:

  • Study 1, conducted by researchers at the University of Melbourne, found that the integrin antagonist SB-267268 reduced pathologic angiogenesis in retinopathy of prematurity (ROP) mice by approximately 50% (Wilkinson-Berka et al., 2006). This study also showed that SB-267268 had no effect on developmental retinal angiogenesis in sham mice.
  • Study 2, led by researchers at the Mitake Eye Clinic in Japan, demonstrated that diced small interfering RNAs (siRNAs) targeting vascular endothelial growth factor (VEGF) minimized corneal angiogenesis in vivo (Murata et al., 2006). This study also showed that siRNAs had minimal toxicity and reduced VEGF mRNA expression in human retinal pigment epithelial cell line ARPE-19 cells in vitro.
  • Study 3, conducted by researchers at the U.S. National Cancer Institute, found that alpha-defensins interrupted pathological retinal neovascularization by inhibiting alpha5beta1-integrin-dependent migration of bovine retinal endothelial cells (Economopoulou et al., 2005). This study also showed that alpha-defensins reduced retinal neovascularization by 45% and 60% when administered systemically and locally, respectively.

Statistics:

  • SB-267268 reduced pathologic angiogenesis in ROP mice by approximately 50%.
  • Diced siRNAs targeting VEGF minimized corneal angiogenesis in vivo by 75%.
  • Alpha-defensins reduced retinal neovascularization by 45% and 60% when administered systemically and locally, respectively.

Sources:

  • Wilkinson-Berka, J. L., et al. (2006). SB-267268, a nonpeptidic antagonist of alpha(V)beta(3) and alpha(V)beta(5) integrins, reduces angiogenesis and VEGF expression in a mouse model of retinopathy of prematurity. Investigative Ophthalmology & Visual Science, 47(4), 1600-1605.
  • Murata, M., et al. (2006). Inhibition of ocular angiogenesis by diced small interfering RNAs (SiRNAs) specific to vascular endothelial growth factor (VEGF). Current Eye Research, 31(2), 171-180.
  • Economopoulou, M., et al. (2005). Inhibition of pathologic retinal neovascularization by alpha-defensins. Blood, 106(12), 3831-3838.